Uruchamianie technologii w badaniu dotyczącym ryzyka cukrzycy typu 1 (STAR-T1D)
Wdrożenie technologii w badaniu dotyczącym osób zagrożonych cukrzycą typu 1 (STAR-T1D).
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Estelle M Everett, MD, MHS
- Numer telefonu: 310-267-0625
- E-mail: eeverett@mednet.ucla.edu
Lokalizacje studiów
-
-
California
-
Santa Monica, California, Stany Zjednoczone, 90404
- Rekrutacyjny
- UCLA
-
Kontakt:
- Rebecca Lopez, BA
- Numer telefonu: (310) 882-0033
- E-mail: rebeccalopez@mednet.ucla.edu
-
Kontakt:
- Erin E Shaw, B.S.
- E-mail: EEShaw@mednet.ucla.edu
-
Sylmar, California, Stany Zjednoczone, 91342
- Rekrutacyjny
- Olive View-UCLA Medical Center
-
Kontakt:
- Hugo Torres, MD
- Numer telefonu: 747-210-3000
- E-mail: HATorres@mednet.ucla.edu
-
Torrance, California, Stany Zjednoczone, 90502
- Rekrutacyjny
- Harbor-UCLA Medical Center
-
Kontakt:
- Joyce A Graham
- Numer telefonu: (310) 222-1870
- E-mail: jgraham@lundquist.org
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Type 1 Diabetes
- A1c ≥ 8.0%
- Not insulin pump user
- Primary language of English or Spanish
- Have medical insurance coverage
Exclusion Criteria:
- No measured A1c in the past year
- Have comorbidities that can result in inaccurate hemoglobin A1c
- Have cognitive, physical or mental impairment precluding diabetes technology use
- Limited life expectancy (<1 year)
- Pregnancy
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Hybrid Closed Loop Insulin Pump System
Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Patients will be started on an automated insulin delivery system. |
|
Brak interwencji: Control
Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of screened participants that are eligible
Ramy czasowe: 6 months
|
Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data. |
6 months
|
|
Proportion of enrolled participants that are randomized
Ramy czasowe: 6 months
|
Randomized among enrolled, and receiving allocated intervention among randomized. |
6 months
|
|
Proportion of average time delay to enrollment
Ramy czasowe: 6 months
|
Average time delay from screening to enrollment. |
6 months
|
|
Proportion of retention among participants randomized to the Intervention Group
Ramy czasowe: 6 months
|
Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized. |
6 months
|
|
Proportion of retention among participants randomized
Ramy czasowe: 6 months
|
Participants lost to follow-up among those initially randomized. |
6 months
|
|
Proportion of retention among participants randomized
Ramy czasowe: 6 months
|
Retention rates by participants completing all research assessments among randomized. |
6 months
|
|
Number of participants who adhere to assigned treatment
Ramy czasowe: 6 months
|
Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed. Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. |
6 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in A1c
Ramy czasowe: 6 months
|
Serum Hemoglobin A1c laboratory measurement |
6 months
|
|
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
Ramy czasowe: 6 months
|
Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl. |
6 months
|
|
Mean Diabetes Ketoacidosis Episodes Incidence
Ramy czasowe: 6 months
|
Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews. |
6 months
|
|
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
Ramy czasowe: 6 months
|
Number of diabetes related ED visits or hospitalizations |
6 months
|
|
Treatment Burden and Satisfaction: Diabetes Distress
Ramy czasowe: 6 months
|
Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5. |
6 months
|
|
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
Ramy czasowe: 6 months
|
Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life. |
6 months
|
|
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
Ramy czasowe: 6 months
|
Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each. |
6 months
|
|
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
Ramy czasowe: 6 months
|
Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome. WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9. |
6 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 22-000236
- 5K23DK132482-02 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .